Xadago (Safinamide Mesylate) Patent Expiration, LOE Window & CMS Spending

Xadago (Safinamide Mesylate) by Mdd Us Operations: FDA Orange Book core substance LOE 2028-12-10 (last listed 2031-03-21), 3 AB generics, $7.9M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMdd Us Operations
FDA Application & PathwayN207145 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2028-12-10
Last Listed Patent or Exclusivity Date2031-03-21
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$7.9M
2024 Medicare Part D Spend$7.7M
2024 Medicaid Spend$270K
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 26.0% 2-yr change)